Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Eisai Co. Ltd.; Lymphoma Study Association; and Boehringer Ingelheim. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-229-5872
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10 million
Profitability
Miscellaneous
Employees131
OptionableOptionable
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme Inc (NASDAQ:EPZM) released its quarterly earnings results on Friday, November, 2nd. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the Zacks' consensus estimate of ($0.61) by $0.07. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
9 brokers have issued 12-month price objectives for Epizyme's shares. Their forecasts range from $11.00 to $27.00. On average, they expect Epizyme's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 123.3% from the stock's current price. View Analyst Price Targets for Epizyme.
What is the consensus analysts' recommendation for Epizyme?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.
Has Epizyme been receiving favorable news coverage?
News coverage about EPZM stock has trended very positive this week, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Epizyme earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Endo International (ENDP), Arena Pharmaceuticals (ARNA), Opko Health (OPK), Mirati Therapeutics (MRTX), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD) and Supernus Pharmaceuticals (SUPN).
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
- Mr. Matthew E. Ros, Chief Strategy & Bus. Officer (Age 52)
- Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
- Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
- Ms. Suzanne Fleming, Principal Financial Officer, Sr. VP of Fin., Treasurer & Principal Accounting Officer (Age 58)
Who are Epizyme's major shareholders?
Epizyme's stock is owned by a variety of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (8.69%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.
Which institutional investors are buying Epizyme stock?
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $9.18.
How big of a company is Epizyme?
Epizyme has a market capitalization of $756.85 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.
What is Epizyme's official website?
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
